JUBLPHARMA Financial Statements

Jubilant Pharmova Key Financial Ratios

Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2021 Mar-2020 Mar-2018 Mar-2017
Growth matrix (%)        
Revenue growth (33) 21.80 28.30 1.95
Op profit growth (28) 28.20 12.90 7.89
EBIT growth (30) 34 5.99 18.10
Net profit growth (6.90) 39.70 11.70 46.90
Profitability ratios (%)        
OPM 22.90 21.30 20.20 23
EBIT margin 17.50 16.70 15.20 18.40
Net profit margin 13.70 9.81 8.55 9.82
RoCE 11.50 16.70 15 14.20
RoNW 4.04 4.63 4.27 4.50
RoA 2.26 2.45 2.10 1.89
Per share ratios ()        
EPS 52.50 56.40 40.70 36.90
Dividend per share 5 5 3 3
Cash EPS 30.60 27.40 14.60 18.30
Book value per share 298 352 262 221
Valuation ratios        
P/E 13 3.83 17.90 18.80
P/CEPS 22.30 7.88 49.80 38
P/B 2.29 0.61 2.78 3.14
EV/EBIDTA 9.19 3.70 10.70 11.90
Payout (%)        
Dividend payout -- -- 7.27 8.12
Tax payout (34) (25) (26) (22)
Liquidity ratios        
Debtor days 63.20 48.30 51.90 60.90
Inventory days 89 64.50 63.40 75.50
Creditor days (65) (58) (60) (58)
Leverage ratios        
Interest coverage (5.80) (5.30) (4) (3.20)
Net debt / equity 0.46 0.61 0.79 1.04
Net debt / op. profit 1.55 1.75 2.12 2.67
Cost breakup ()        
Material costs (25) (34) (38) (34)
Employee costs (32) (23) (21) (21)
Other costs (20) (21) (21) (22)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar( In .Cr) Mar-2021 Mar-2020 Mar-2018 Mar-2017
Revenue 6,099 9,154 7,518 5,861
yoy growth (%) (33) 21.80 28.30 1.95
Raw materials (1,536) (3,141) (2,869) (1,999)
As % of sales 25.20 34.30 38.20 34.10
Employee costs (1,923) (2,128) (1,556) (1,231)
As % of sales 31.50 23.20 20.70 21
Other costs (1,243) (1,939) (1,575) (1,286)
As % of sales 20.40 21.20 20.90 21.90
Operating profit 1,396 1,947 1,518 1,345
OPM 22.90 21.30 20.20 23
Depreciation (349) (462) (415) (291)
Interest expense (184) (287) (284) (341)
Other income 17.60 47.40 40 24.90
Profit before tax 881 1,245 859 738
Taxes (297) (312) (225) (163)
Tax rate (34) (25) (26) (22)
Minorities and other 262 -- 8.39 1.03
Adj. profit 846 933 643 576
Exceptional items (21) (35) -- --
Net profit 836 898 643 576
yoy growth (%) (6.90) 39.70 11.70 46.90
NPM 13.70 9.81 8.55 9.82
Switch to
Tabular Data
Graph
Y/e 31 Mar ( In .Cr) Mar-2021 Mar-2020 Mar-2018 Mar-2017
Profit before tax 881 1,245 859 738
Depreciation (349) (462) (415) (291)
Tax paid (297) (312) (225) (163)
Working capital 563 2,289 47 92.30
Other operating items -- -- -- --
Operating cashflow 798 2,760 266 376
Capital expenditure 926 1,899 (581) (1,658)
Free cash flow 1,724 4,659 (315) (1,283)
Equity raised 6,046 6,931 5,935 5,503
Investments 208 50.20 97.90 68.70
Debt financing/disposal 1,385 2,048 1,269 3,795
Dividends paid -- -- 46.70 46.70
Other items -- -- -- --
Net in cash 9,363 13,688 7,033 8,130
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2021 Mar-2020 Mar-2019 Mar-2018
Equity capital 15.90 15.90 15.90 15.60
Preference capital -- -- -- --
Reserves 4,726 5,588 4,793 4,071
Net worth 4,741 5,604 4,809 4,087
Minority interest
Debt 2,830 4,808 4,840 3,469
Deferred tax liabilities (net) 247 263 202 163
Total liabilities 7,818 10,676 9,852 7,667
Fixed assets 5,506 7,108 6,550 6,072
Intangible assets
Investments 241 69.40 115 124
Deferred tax asset (net) 155 211 150 160
Net working capital 1,246 1,887 1,667 1,063
Inventories 1,129 1,845 1,417 1,391
Inventory Days 67.60 73.60 -- 67.60
Sundry debtors 820 1,293 1,272 1,131
Debtor days 49.10 51.60 -- 54.90
Other current assets 396 594 595 491
Sundry creditors (554) (1,125) (1,083) (1,177)
Creditor days 33.20 44.80 -- 57.10
Other current liabilities (546) (721) (533) (774)
Cash 671 1,400 1,370 249
Total assets 7,818 10,676 9,852 7,667
Switch to
Consolidated
Standalone


Particulars ( Rupees In Crores.) Dec-2021 Sep-2021 Jun-2021 Mar-2021 Dec-2020
Gross Sales 1,298 1,634 1,613 1,552 1,744
Excise Duty -- -- -- -- --
Net Sales 1,298 1,634 1,613 1,552 1,744
Other Operating Income 12.90 23.80 21.20 28.10 27.70
Other Income 5.94 4.45 3.89 62 94.50
Total Income 1,316 1,662 1,639 1,642 1,866
Total Expenditure ** 1,116 1,319 1,269 1,216 1,293
PBIDT 200 343 369 426 573
Interest 36.60 34.70 34.60 43.30 46.40
PBDT 164 308 335 383 527
Depreciation 93.30 99.80 88 86.20 95.90
Minority Interest Before NP -- -- -- -- --
Tax 8.25 58.20 65.30 83.10 94.50
Deferred Tax 11.20 7.22 20.80 -- 26.70
Reported Profit After Tax 50.80 143 160 214 310
Minority Interest After NP (0.20) (0.20) (0.10) (0.30) (0.10)
Net Profit after Minority Interest 51 143 161 214 310
Extra-ordinary Items -- -- -- (7) (7)
Adjusted Profit After Extra-ordinary item 51 143 161 221 317
EPS (Unit Curr.) 3.20 8.97 10.10 13.40 19.50
Book Value (Unit Curr.) -- -- -- -- --
Dividend (%) -- -- -- -- --
Equity 15.90 15.90 15.90 15.90 15.90
Public Shareholding (Number) -- -- -- -- --
Public Shareholding (%) -- -- -- -- --
Pledged/Encumbered - No. of Shares -- -- -- -- --
Pledged/Encumbered - % in Total Promoters Holding -- -- -- -- --
Pledged/Encumbered - % in Total Equity -- -- -- -- --
Non Encumbered - No. of Shares -- -- -- -- --
Non Encumbered - % in Total Promoters Holding -- -- -- -- --
Non Encumbered - % in Total Equity -- -- -- -- --
PBIDTM(%) 15.40 21 22.90 27.50 32.90
PBDTM(%) 12.60 18.80 20.70 24.70 30.20
PATM(%) 3.91 8.73 9.95 13.80 17.80
Open ZERO Brokerage Demat Account
Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity